Company Overview of Symphony Evolution, Inc.
Symphony Evolution, Inc., a biopharmaceutical company, develops therapeutics to treat cancer and diabetic nephropathy. It involves in the development of clinical programs, including XL647, a potent inhibitor of receptor tyrosine kinases (RTK); XL999 that inhibits RTKs implicated in the development and maintenance of tumor vasculature; and XL784, a small molecule compound for renal disease. The company was incorporated in 2005 and is based in Rockville, Maryland.
7361 Calhoun Place
Rockville, MD 20855
Founded in 2005
Key Executives for Symphony Evolution, Inc.
Similar Private Companies By Industry
|Pharmacare Inc.||United States|
|Silamed, Inc.||United States|
|Contract Pharmacal Corp.||United States|
|Daiichi Sankyo, Inc.||United States|
|Legacy Pharmaceuticals Puerto Rico, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Symphony Evolution, Inc., please visit www.symphonyevolution.com. Company data is provided by Capital IQ. Please use this form to report any data issues.